Lyndsay Harris, M.D.

Associate Director

Dr. Lyndsay Harris comes to the NCI from a 30 year career in breast cancer research and translational science. She has over 170 publications and has led Breast Cancer programs at Yale University and Case Western Reserve University where her lab studied the genomics of resistance to HER2 positive breast cancer and disparities in triple negative breast cancer. As Associate Director of the Cancer Diagnosis Program her role is to direct her team in the development of robust prognostic and therapeutic biomarkers through the study of biospecimen science, technology and innovation, pathology evaluation and genomics. The Cancer Diagnosis Program works closely with the Cancer Therapy Evaluation Program (CTEP) to implement biomarkers into several Precision Medicine trials including the NCI-MATCH (Molecular Analysis for Therapy Choice) trial where Dr. Harris serves as a Co-PI and ComboMATCH (a study of novel combination therapies) which she co-leads with Jeff Moscow of CTEP. In addition, Dr. Harris manages the MDNet assay network that has been set up to run molecular assays on three new Precision Medicine trials.